Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Belite Bio, IncNASDAQ: BLTE
Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026
Weighted avg shares growth accelerates
Q3 FY2026 weighted avg shares of 40.42M shares rose 21.6% year over year, ahead of the +19.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.6% holds above the trailing-twelve-month pace of +19.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 33.54M USD
- Year-over-year change
- +9.8%
- 4-year CAGR
- +8.6%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.54M | +9.8% |
| FY2024 | 2024-12-31 | 30.54M | +14.8% |
| FY2023 | 2023-12-31 | 26.59M | +33.1% |
| FY2022 | 2022-12-31 | 19.98M | -17.1% |
| FY2021 | 2021-12-31 | 24.1M | — |
Weighted Avg Shares vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Sep 2026 weighted avg shares of 38.5M shares is the 5th highest of the 6 companies compared; the peer median is 77.28M shares.
- Its year-over-year change of +19.1% is the 4th highest of 6, against a peer median of +27.7%.
- Over three fiscal years its annual growth of +18.9% compares with a peer median of +25.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | 406.29M | +1283.9% | +214.9% |
| LTM Mar 2026 | 307.2M | +9.9% | +11.8% | |
| LTM Mar 2026 | 77.28M | +27.7% | +25.2% | |
| LTM Sep 2026 | 60.16M | +14.0% | +0.6% | |
BLTEBelite Bio, Inc | LTM Sep 2026 | 38.5M | +19.1% | +18.9% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | 21.01M | +341.4% | +66.1% |
| Peer median (excluding BLTE) | 77.28M | +27.7% | +25.2% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| Weighted Avg Shares | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
| Weighted Avg Shares (Diluted) | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.